Company registration number 15579724 (England and Wales)
JUBILEE PHARMA LTD
UNAUDITED FINANCIAL STATEMENTS
FOR THE PERIOD ENDED 31 MARCH 2025
JUBILEE PHARMA LTD
CONTENTS
Page
Balance sheet
1
Notes to the financial statements
2
JUBILEE PHARMA LTD
BALANCE SHEET
AS AT 31 MARCH 2025
31 March 2025
- 1 -
2025
Notes
£
£
Current assets
Debtors
3
1
Net current assets
1
Capital and reserves
Called up share capital
1

For the financial period ended 31 March 2025 the company was entitled to exemption from audit under section 480 of the Companies Act 2006 relating to dormant companies.

The members have not required the company to obtain an audit of its financial statements for the period in question in accordance with section 476.

The directors acknowledge their responsibilities for complying with the requirements of the Companies Act 2006 with respect to accounting records and the preparation of financial statements.

These financial statements have been prepared and delivered in accordance with the provisions applicable to companies subject to the small companies regime.

The directors of the company have elected not to include a copy of the profit and loss account within the financial statements.true

The financial statements were approved by the board of directors and authorised for issue on 15 October 2025 and are signed on its behalf by:
Mohammed Azim
Director
Company registration number 15579724 (England and Wales)
JUBILEE PHARMA LTD
NOTES TO THE FINANCIAL STATEMENTS
FOR THE PERIOD ENDED 31 MARCH 2025
- 2 -
1
Accounting policies
Company information

Jubilee Pharma Ltd is a private company limited by shares incorporated in England and Wales. The registered office is 55-58 Jubilee Cresent, Coventry, CV6 3ET.

1.1
Reporting period

The reporting period is from 20 March 2024 to 31 March 2025. This ties in with the date of incorporation of the company.

1.2
Basis of preparation

These financial statements have been prepared in accordance with FRS 102 “The Financial Reporting Standard applicable in the UK and Republic of Ireland” (“FRS 102”) and the requirements of the Companies Act 2006 as applicable to companies subject to the small companies regime. The disclosure requirements of section 1A of FRS 102 have been applied other than where additional disclosure is required to show a true and fair view.

The financial statements are prepared in sterling, which is the functional currency of the company. Monetary amounts in these financial statements are rounded to the nearest £.

The financial statements have been prepared under the historical cost convention. The principal accounting policies adopted are set out below.

1.3
Going concern

Atruet the time of approving the financial statements, the directors have a reasonable expectation that the company has adequate resources to continue in operational existence for the foreseeable future. Thus the directors continue to adopt the going concern basis of accounting in preparing the financial statements.

1.4
Profit and loss account

The company has not traded during the period. During this time, the company received no income and incurred no expenditure and therefore no Profit and loss account is presented in these financial statements.

2
Employees

The average monthly number of persons (including directors) employed by the company during the period was:

2025
Number
Total
0
3
Debtors
2025
Amounts falling due within one year:
£
Other debtors
1
4
Ultimate Controlling Party

The company is controlled by Baraa Alzabin.

2025-03-312024-03-20falsefalsetrue15 October 2025CCH SoftwareCCH Accounts Production 2025.200No description of principal activityBaraa AlzabinMohammed Azim155797242024-03-202025-03-31155797242025-03-3115579724core:ShareCapital2025-03-3115579724bus:Director22024-03-202025-03-3115579724core:WithinOneYear2025-03-3115579724bus:EntityHasNeverTraded2024-03-202025-03-3115579724bus:PrivateLimitedCompanyLtd2024-03-202025-03-3115579724bus:SmallCompaniesRegimeForAccounts2024-03-202025-03-3115579724bus:FRS1022024-03-202025-03-3115579724bus:AuditExemptWithAccountantsReport2024-03-202025-03-3115579724bus:Director12024-03-202025-03-3115579724bus:FullAccounts2024-03-202025-03-31xbrli:purexbrli:sharesiso4217:GBP